Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
491.40    -13.10 (-2.60%)
Bid:
498.00
Ask:
500.00
Spread: 2.00 (0.402%)
Market Cap: £2.17b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Judgment re litigation

29 Sep 2015 14:58

29 September 2015 – Tate & Lyle PLC

Judgment handed down in litigation regarding sale of EU Sugars business in 2010

Tate & Lyle PLC (Tate & Lyle) announces that Judgment was handed down today at the Commercial Court in London in the case brought by American Sugar Refining, Inc. (“ASR”) in which it made a number of claims totalling around £40 million in relation to its acquisition of Tate & Lyle’s EU Sugars business in September 2010 for a consideration of £211 million. The Court found in favour of ASR on two elements of its claims, whilst rejecting all other aspects. Accordingly, in the Judgment, the Court has awarded damages of £18 million (€24.9 million) to ASR (with interest and costs to be determined in due course).

This claim has been disclosed in Tate & Lyle’s Annual Report since 2012 and the expected announcement of this Judgement was highlighted in the Trading Statement on 29 July 2015.

The impact of the Judgment will be reported as an exceptional item within discontinued operations.

END

For more information contact Tate & Lyle PLC:Christopher Marsh, VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media RelationsTel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2015, Tate & Lyle sales totalled £2.7 billion. For more information, please visit http://www.tateandlyle.com. SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150929006222/en/

Copyright Business Wire 2015

Date   Source Headline
6th Nov 20257:00 amRNSHalf-year Financial Report
5th Nov 20252:15 pmRNSHolding(s) in Company
3rd Nov 20255:00 pmRNSHolding(s) in Company
29th Oct 20252:00 pmRNSHolding(s) in Company
23rd Oct 20254:15 pmRNSHolding(s) in Company
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement
2nd Sep 20258:00 amRNSTotal Voting Rights
11th Aug 20251:00 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSDirector/PDMR Shareholding
1st Aug 202511:00 amRNSTotal Voting Rights
24th Jul 20252:30 pmRNSResult of Annual General Meeting 2025
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
1st Jul 20253:30 pmRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTate & Lyle Capital Markets Event
13th Jun 20253:00 pmRNSHolding(s) in Company
11th Jun 20254:30 pmRNSDirector/PDMR Shareholding
5th Jun 20252:30 pmRNSAnnual Financial Report and Notice of Meeting 2025
5th Jun 20252:00 pmRNSDirector/PDMR Shareholding
2nd Jun 202512:30 pmRNSTotal Voting Rights
28th May 202512:00 pmRNSDirector/PDMR Shareholding
27th May 202512:00 pmRNSDirector/PDMR Shareholding
23rd May 202510:00 amRNSDirector/PDMR Shareholding
22nd May 20257:00 amRNSFinal Results
14th May 20259:00 amRNSHolding(s) in Company
1st May 20253:00 pmRNSHolding(s) in Company
29th Apr 20253:30 pmRNSHolding(s) in Company
28th Apr 20255:15 pmRNSHolding(s) in Company
24th Apr 202512:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSIntegration update and pre-close statement
27th Mar 20257:00 amRNSDirectorate Change
14th Mar 202510:05 amRNSDirectorate declaration
11th Mar 20253:00 pmRNSHolding(s) in Company
5th Mar 202511:30 amRNSDirector/PDMR Shareholding
28th Feb 20254:30 pmRNSHolding(s) in Company
28th Feb 202510:15 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAdditional Listing
20th Feb 20251:42 pmRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSTrading Statement
4th Feb 20257:05 amRNSDirector Declaration
3rd Feb 20253:30 pmRNSTotal Voting Rights
23rd Jan 20255:30 pmRNSIssue of Debt
9th Jan 20255:54 pmRNSCompletion of Share Buyback Programme
9th Jan 20255:45 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.